S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.73 (-0.77%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.95 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-2.06%)
GE   106.30 (+0.22%)
DIS   91.93 (-0.65%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.73 (-0.77%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.95 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-2.06%)
GE   106.30 (+0.22%)
DIS   91.93 (-0.65%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.73 (-0.77%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.95 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-2.06%)
GE   106.30 (+0.22%)
DIS   91.93 (-0.65%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.73 (-0.77%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.95 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-2.06%)
GE   106.30 (+0.22%)
DIS   91.93 (-0.65%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
NYSE:RMD

ResMed (RMD) Stock Forecast, Price & News

$213.53
-1.40 (-0.65%)
(As of 04:33 PM ET)
Compare
Today's Range
$212.62
$215.40
50-Day Range
$209.98
$240.96
52-Week Range
$194.30
$247.65
Volume
511,996 shs
Average Volume
623,623 shs
Market Capitalization
$31.37 billion
P/E Ratio
36.38
Dividend Yield
0.82%
Price Target
$263.43

ResMed MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.78 Rating Score
Upside/​Downside
23.4% Upside
$263.43 Price Target
Short Interest
Healthy
0.71% of Shares Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
-0.55
Upright™ Environmental Score
News Sentiment
0.14mentions of ResMed in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$7.26 M Sold Last Quarter
Proj. Earnings Growth
12.04%
From $6.48 to $7.26 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.62 out of 5 stars

Medical Sector

102nd out of 986 stocks

Surgical & Medical Instruments Industry

13th out of 98 stocks


RMD stock logo

About ResMed (NYSE:RMD) Stock

ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. The firm operates through the Sleep and Respiratory Care and Software as a Service segments. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The Software as a Service segment provides business management software as a service to out-of-hospital health providers. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.

Receive RMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ResMed and its competitors with MarketBeat's FREE daily newsletter.

RMD Stock News Headlines

Free Stock Analysis Report with Predictive Buy/Sell/Hold Insights
Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.
Medical Equipment Stock to Add to Your Portfolio
ResMed (NYSE:RMD) Lifted to Buy at StockNews.com
ResMed (NYSE:RMD) Cut to Hold at StockNews.com
Free Stock Analysis Report with Predictive Buy/Sell/Hold Insights
Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.
ResMed (NYSE:RMD) Now Covered by UBS Group
Analysts Set ResMed Inc. (NYSE:RMD) Target Price at $259.00
ResMed (NYSE:RMD) Raised to "Buy" at StockNews.com
ResMed Inc. (NYSE:RMD) Insider Sells $119,650.00 in Stock
Brokerages Set ResMed Inc. (NYSE:RMD) Target Price at $259.00
ResMed (RMD) Set to Announce Earnings on Thursday
ResMed Inc. (NYSE:RMD) COO Sells $336,975.00 in Stock
See More Headlines

RMD Price History

RMD Company Calendar

Ex-Dividend for 3/16 Dividend
2/08/2023
Dividend Payable
3/16/2023
Last Earnings
4/27/2023
Ex-Dividend for 6/15 Dividend
5/10/2023
Today
6/09/2023
Dividend Payable
6/15/2023
Fiscal Year End
6/30/2023
Next Earnings (Estimated)
8/10/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
CUSIP
76115210
Employees
8,160
Year Founded
1989

Price Target and Rating

Average Stock Price Forecast
$263.43
High Stock Price Forecast
$290.00
Low Stock Price Forecast
$245.00
Forecasted Upside/Downside
+22.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

Net Income
$779.44 million
Pretax Margin
26.47%

Debt

Sales & Book Value

Annual Sales
$3.58 billion
Cash Flow
$7.14 per share
Book Value
$22.97 per share

Miscellaneous

Free Float
144,889,000
Market Cap
$31.58 billion
Optionable
Optionable
Beta
0.48

Social Links


Key Executives

  • Mick Farrell
    Chairman & Chief Executive Officer
  • Rob Douglas
    President & Chief Operating Officer
  • Brett A. SandercockBrett A. Sandercock
    Chief Financial Officer
  • Carlos M. Nunez
    Chief Medical Officer
  • Urvashi Tyagi
    Chief Technology Officer













RMD Stock - Frequently Asked Questions

Should I buy or sell ResMed stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RMD shares.
View RMD analyst ratings
or view top-rated stocks.

What is ResMed's stock price forecast for 2023?

9 analysts have issued 1 year price objectives for ResMed's stock. Their RMD share price forecasts range from $245.00 to $290.00. On average, they predict the company's share price to reach $263.43 in the next year. This suggests a possible upside of 22.6% from the stock's current price.
View analysts price targets for RMD
or view top-rated stocks among Wall Street analysts.

How have RMD shares performed in 2023?

ResMed's stock was trading at $208.13 on January 1st, 2023. Since then, RMD stock has increased by 3.3% and is now trading at $214.92.
View the best growth stocks for 2023 here
.

When is ResMed's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our RMD earnings forecast
.

How were ResMed's earnings last quarter?

ResMed Inc. (NYSE:RMD) posted its quarterly earnings results on Thursday, April, 27th. The medical equipment provider reported $1.68 EPS for the quarter, beating the consensus estimate of $1.58 by $0.10. The medical equipment provider earned $1.12 billion during the quarter, compared to the consensus estimate of $1.05 billion. ResMed had a trailing twelve-month return on equity of 25.82% and a net margin of 21.49%. ResMed's revenue for the quarter was up 29.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.32 EPS.
Read the conference call transcript
.

How often does ResMed pay dividends? What is the dividend yield for ResMed?

ResMed declared a quarterly dividend on Thursday, April 27th. Shareholders of record on Thursday, May 11th will be given a dividend of $0.44 per share on Thursday, June 15th. This represents a $1.76 annualized dividend and a dividend yield of 0.82%. The ex-dividend date is Wednesday, May 10th.
Read our dividend analysis for RMD
.

Is ResMed a good dividend stock?

ResMed (NYSE:RMD) pays an annual dividend of $1.76 per share and currently has a dividend yield of 0.82%. The company has been increasing its dividend for 2 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 29.98%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, RMD will have a dividend payout ratio of 24.24% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for RMD.

What is Mick Farrell's approval rating as ResMed's CEO?

284 employees have rated ResMed Chief Executive Officer Mick Farrell on Glassdoor.com. Mick Farrell has an approval rating of 92% among the company's employees. This puts Mick Farrell in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ResMed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ResMed investors own include NVIDIA (NVDA), Walt Disney (DIS), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Adobe (ADBE), Visa (V), Alibaba Group (BABA), PayPal (PYPL) and QUALCOMM (QCOM).

What is ResMed's stock symbol?

ResMed trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMD."

Who are ResMed's major shareholders?

ResMed's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.94%), FMR LLC (4.42%), State Street Corp (4.28%), WCM Investment Management LLC (2.37%), Geode Capital Management LLC (2.20%) and Ownership Capital B.V. (0.95%). Insiders that own company stock include Brett Sandercock, Carol Burt, Dave Michaud, David Pendarvis, James Hollingshead, Justin Leong, Karen Drexler, Kaushik Ghoshal, Lucile Blaise, Michael J Farrell, Peter C Farrell, Rajwant Sodhi, Robert Andrew Douglas and Ronald R Taylor.
View institutional ownership trends
.

How do I buy shares of ResMed?

Shares of RMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ResMed's stock price today?

One share of RMD stock can currently be purchased for approximately $214.92.

How much money does ResMed make?

ResMed (NYSE:RMD) has a market capitalization of $31.58 billion and generates $3.58 billion in revenue each year. The medical equipment provider earns $779.44 million in net income (profit) each year or $5.87 on an earnings per share basis.

How many employees does ResMed have?

The company employs 8,160 workers across the globe.

Does ResMed have any subsidiaries?
The following companies are subsidiares of ResMed: Matrixcare, and Propeller Health.
Read More
How can I contact ResMed?

ResMed's mailing address is 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA, 92123. The official website for the company is www.resmed.com. The medical equipment provider can be reached via phone at (858) 836-5000, via email at investorrelations@resmed.com, or via fax at 858-836-5501.

This page (NYSE:RMD) was last updated on 6/9/2023 by MarketBeat.com Staff

My Account -